About DAMAE Medical

DAMAE Medical develops the deepLive™ imaging system, which utilizes line-field confocal optical coherence tomography (LC-OCT) technology to provide high-resolution, 3D imaging of skin lesions. This non-invasive method significantly reduces the rate of unnecessary biopsies and improves early detection of skin cancers, addressing the challenge of missed diagnoses in clinical practice.

```xml <problem> Current methods for diagnosing skin cancer, such as dermoscopy, have limitations in sensitivity, leading to missed early-stage cancers and unnecessary biopsies of benign lesions. These diagnostic uncertainties can result in delayed treatment and increased patient morbidity. </problem> <solution> DAMAE Medical's deepLive™ imaging system utilizes Line-field Confocal Optical Coherence Tomography (LC-OCT) to provide high-resolution, 3D imaging of skin lesions, offering a non-invasive alternative to traditional biopsy. The deepLive™ system allows clinicians to visualize skin structures at a cellular level, enabling more accurate differentiation between benign and malignant lesions. By providing detailed subsurface images, deepLive™ reduces the need for unnecessary biopsies and improves the early detection of skin cancers. The system's 3D imaging capabilities facilitate comprehensive assessment of skin conditions, promoting efficient and reassuring patient management. </solution> <features> - Line-field Confocal Optical Coherence Tomography (LC-OCT) technology for high-resolution 3D imaging - Non-invasive imaging of skin lesions, reducing the need for biopsies - Vertical and horizontal imaging modes for comprehensive visualization - Quantitative skin analysis, including 3D segmentation of skin surface and dermo-epidermal junction - Analysis of keratinocyte distribution and density, as well as collagen fiber segmentation - Integration of live dermoscopic camera inside the LC-OCT 3D handheld probe </features> <target_audience> The primary users are dermatologists, oncologists, and other medical professionals involved in skin cancer diagnosis and treatment, as well as research institutions focused on dermatology and oncology. </target_audience> ```

What does DAMAE Medical do?

Where is DAMAE Medical located?

DAMAE Medical is based in Paris, France.

When was DAMAE Medical founded?

DAMAE Medical was founded in 2014.

How much funding has DAMAE Medical raised?

DAMAE Medical has raised 5700000.

Location

Paris, France

Founded

2014

Funding

5700000

Employees

33 employees

Major Investors

BNP Paribas Développement

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

DAMAE Medical

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

damae-medical.com 5K+

Crunchbase

Founded 2014 – Paris, France

Funding

Estimated Funding

$5M+

Major Investors

BNP Paribas Développement

Team (30+)

No team information available.

Company Description

Problem

Current methods for diagnosing skin cancer, such as dermoscopy, have limitations in sensitivity, leading to missed early-stage cancers and unnecessary biopsies of benign lesions. These diagnostic uncertainties can result in delayed treatment and increased patient morbidity.

Solution

DAMAE Medical's deepLive™ imaging system utilizes Line-field Confocal Optical Coherence Tomography (LC-OCT) to provide high-resolution, 3D imaging of skin lesions, offering a non-invasive alternative to traditional biopsy. The deepLive™ system allows clinicians to visualize skin structures at a cellular level, enabling more accurate differentiation between benign and malignant lesions. By providing detailed subsurface images, deepLive™ reduces the need for unnecessary biopsies and improves the early detection of skin cancers. The system's 3D imaging capabilities facilitate comprehensive assessment of skin conditions, promoting efficient and reassuring patient management.

Features

Line-field Confocal Optical Coherence Tomography (LC-OCT) technology for high-resolution 3D imaging

Non-invasive imaging of skin lesions, reducing the need for biopsies

Vertical and horizontal imaging modes for comprehensive visualization

Quantitative skin analysis, including 3D segmentation of skin surface and dermo-epidermal junction

Analysis of keratinocyte distribution and density, as well as collagen fiber segmentation

Integration of live dermoscopic camera inside the LC-OCT 3D handheld probe

Target Audience

The primary users are dermatologists, oncologists, and other medical professionals involved in skin cancer diagnosis and treatment, as well as research institutions focused on dermatology and oncology.